Innovating Works

H2020

Cerrada
DIGITAL-2024-CLOUD-DATA-0...
DIGITAL-2024-CLOUD-DATA-06-HEALTHCARE-AI: Support for Health Data Access Bodies to foster efficient pathways for AI in healthcare
ExpectedOutcome:Deliverables
Sólo fondo perdido 4M €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 29-05-2024.
Hace 5 mes(es) del cierre de la convocatoria y aún no tenemos información sobre los proyectos financiados, puede que esta información se publique pronto.
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio..
Esta ayuda financia Proyectos:

ExpectedOutcome:Deliverables

Report on the identified pathways for testing and deployment of AI in health and their limitations and gaps in the current landscape;Description of pathways based on health data access bodies’ services and other key actors such as TEFs and EDIHs, where relevant, in light of the EHDS and the AIA;Guidelines for creating and deploying the necessary capabilities for HDABs to support the development, testing and deployment pathways for AI in healthcare;Reports on the tests and showcases conducted;Recommendations for the implementing of development, testing and deployment pathways of AI in health based on the opportunities offered by the EHDS and the requirements of the AIA.
Objective:Objective

Healthcare demands continue to increase due to factors like population growth, aging populations, and the prevalence of chronic diseases. Healthcare technologies can help meet these demands by, among others, increasing effectiveness of treatment and diagnostic solutions and efficiency of health systems. The deployment of new medical digital technologies and artificial intelligence (AI) powered solutions for healthcare purposes requires... ver más

ExpectedOutcome:Deliverables

Report on the identified pathways for testing and deployment of AI in health and their limitations and gaps in the current landscape;Description of pathways based on health data access bodies’ services and other key actors such as TEFs and EDIHs, where relevant, in light of the EHDS and the AIA;Guidelines for creating and deploying the necessary capabilities for HDABs to support the development, testing and deployment pathways for AI in healthcare;Reports on the tests and showcases conducted;Recommendations for the implementing of development, testing and deployment pathways of AI in health based on the opportunities offered by the EHDS and the requirements of the AIA.
Objective:Objective

Healthcare demands continue to increase due to factors like population growth, aging populations, and the prevalence of chronic diseases. Healthcare technologies can help meet these demands by, among others, increasing effectiveness of treatment and diagnostic solutions and efficiency of health systems. The deployment of new medical digital technologies and artificial intelligence (AI) powered solutions for healthcare purposes requires access to real world health data. The amount of data available to drive the development of AI should be as large as possible to limit the introduction of biases that could undermine the effectiveness and safety of healthcare AI solutions or increase inequalities in access to care.

The European Health Data Space (EHDS) establishes a common framework for the reuse of health data. It aims to facilitate and streamline access to EU-wide real-world health data for specific purposes such as the development, testing, deployment and uptake of products or services contributing to public health or the training, testing and evaluation of algorithms, including in medical devices, AI systems and digital health applications. The proposal for a Regulation on the EHDS provides for Health Data Access Bodies (HDABs) in each country as trusted anchors to support and supervise the reuse of health data.

As part of the wider AI ecosystem in health, such as Testing and Experimentation Facilities (TEFs) for AI and European Digital Innovation Hubs (EDIHs), this action aims to strengthen the role and capabilities of HDABs in streamlining the testing and deployment pathways for healthcare AI solutions.

The aim of this action is also to reduce time-to-market and foster the development of new AI-based healthcare products and services that significantly improve patient safety and wellbeing, while preserving privacy and security. This action is not only relevant to the implementation of the EHDS, but also to the implementation of the Artificial Intelligence Act (AIA), which establishes an overarching framework for trustworthy AI, including in healthcare (e.g. medical devices).


Scope:Scope

The action comprises the following:

Identifying current pathways, i.e. regulatory, organisational and technical processes and means, for the development, testing and deployment of AI in health, as well as limitations, bottlenecks and gaps reducing the overall effectiveness of these pathways; • Designing more effective pathways by leveraging EHDS and Health Data Access Bodies, and possibly Testing and Experimentation Facilities (TEFs) and European Digital Innovation Hubs (EDIHs);Creating and implementing the necessary capabilities at the level of the Health Data Access Bodies to support these pathways for the development, testing and deployment of AI in health, and building around them an appropriate community including where appropriate, data users, data holders, TEFs and EDIHs;Testing and showcasing these pathways with Health Data Access Bodies and the relevant actors in the community, based on specific examples in relevant disease areas, e.g. cancer, mental health or cardiovascular diseases;Providing guidelines and recommendations for improving the development, testing and deployment pathways for AI in health, taking advantage of the opportunities offered by the EHDS.
ver menos

Temáticas Obligatorias del proyecto: Temática principal: The project focuses on developing efficient pathways for AI deployment in healthcare by leveraging the European Health Data Space, Health Data Access Bodies, and other key actors. It aims to streamline testing, development, and deployment of AI solutions to enhance patient safety and wellbeing while ensuring privacy and security.
Healthcare Artificial Intelligence Data Security and Privacy Digital Health Regulatory Processes

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: *Presupuesto para cada participante en el proyecto
Requisitos técnicos: The expected impacts of the project include:

1. Improved effectiveness of treatment and diagnostic solutions in healthcare through the deployment of new medical digital technologies and AI-powered solutions.
2. Increased efficiency of health systems to meet the growing healthcare demands caused by population growth, aging populations, and chronic diseases.
3. Facilitation of access to EU-wide real-world health data for the development, testing, deployment, and uptake of healthcare products and services.
4. Strengthening the role and capabilities of Health Data Access Bodies (HDABs) to streamline testing and deployment pathways for healthcare AI solutions.
5. Reduction in time-to-market for AI-based healthcare products and services that enhance patient safety and wellbeing while ensuring privacy and security.
6. Enhancement of the overall effectiveness of development, testing, and deployment pathways for AI in health by identifying and addressing limitations, bottlenecks, and gaps.
7. Creation of a community involving data users, data holders, Testing and Experimentation Facilities (TEFs), and European Digital Innovation Hubs (EDIHs) to support and supervise the reuse of health data.
8. Provision of guidelines and recommendations to improve pathways for AI in health, leveraging the opportunities offered by the European Health Data Space (EHDS).
9. Testing and showcasing of pathways with relevant actors in disease are...
The expected impacts of the project include:
1. Improved effectiveness of treatment and diagnostic solutions in healthcare through the deployment of new medical digital technologies and AI-powered solutions.
2. Increased efficiency of health systems to meet the growing healthcare demands caused by population growth, aging populations, and chronic diseases.
3. Facilitation of access to EU-wide real-world health data for the development, testing, deployment, and uptake of healthcare products and services.
4. Strengthening the role and capabilities of Health Data Access Bodies (HDABs) to streamline testing and deployment pathways for healthcare AI solutions.
5. Reduction in time-to-market for AI-based healthcare products and services that enhance patient safety and wellbeing while ensuring privacy and security.
6. Enhancement of the overall effectiveness of development, testing, and deployment pathways for AI in health by identifying and addressing limitations, bottlenecks, and gaps.
7. Creation of a community involving data users, data holders, Testing and Experimentation Facilities (TEFs), and European Digital Innovation Hubs (EDIHs) to support and supervise the reuse of health data.
8. Provision of guidelines and recommendations to improve pathways for AI in health, leveraging the opportunities offered by the European Health Data Space (EHDS).
9. Testing and showcasing of pathways with relevant actors in disease areas like cancer, mental health, or cardiovascular diseases to demonstrate the effectiveness of the developed pathways.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Subcontracting costs.
Purchase costs.
Other cost categories.
Indirect costs.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 9:. La tecnología está en su forma final y funciona bajo una amplia gama de condiciones. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Para el presupuesto subvencionable la intensidad de la ayuda en formato fondo perdido podrá alcanzar como minimo un 100%.
The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations. The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations.
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
El presupuesto total de la convocatoria asciende a
Presupuesto total de la convocatoria.
Proyectos financiables en esta convocatoria.
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.
Certificado DNSH: Los proyectos presentados a esta línea deben de certificarse para demostrar que no causan perjuicio al medio ambiente. + info

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.